Evaluation Study of New Compounds With Potential Use in Schizophrenia

NCT00916201 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Schizophrenia

Interventions

DRUG: URB597
DRUG: intranasal Insulin
DRUG: Cannabidiol CR

Sponsor

Central Institute of Mental Health, Mannheim

Collaborators

[object Object]